MannKind Corporation 2023 Form 10-K Summary
Business Context and Reporting Period
MannKind is a biopharmaceutical company developing and commercializing inhaled therapies and delivery devices using its Technosphere and Dreamboat platforms. The filing covers the fiscal year ended December 31, 2023, with comparative information for 2022 and 2021.
- Commercial products: Afrezza inhaled insulin and V-Go wearable insulin delivery device.
- Collaboration product: Tyvaso DPI, commercialized by United Therapeutics, for which MannKind receives manufacturing revenue and royalties.
- Pipeline: MNKD-101 inhaled clofazimine for pulmonary NTM disease and MNKD-201 inhaled nintedanib for idiopathic pulmonary fibrosis.
Financial Performance and Key Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $199.0 million | $99.8 million | +99% |
| Commercial product revenue | $74.0 million | $56.2 million | +32% |
| Collaboration and services revenue | $53.0 million | $27.9 million | +90% |
| Royalty revenue | $72.0 million | $15.6 million | +361% |
| Commercial product gross profit | $53.2 million | $40.2 million | +32% |
| Commercial product gross margin | 72% | 72% | Flat |
| Income (loss) from operations | $8.7 million | $(64.1) million | Improved |
| Net loss | $(11.9) million | $(87.4) million | Improved |
| Basic and diluted loss per share | $(0.04) | $(0.34) | Improved |
| Cash flow from operations | $34.1 million | $(80.7) million | Improved |
- Gross product revenue increased to $130.5 million from $97.0 million. Gross-to-net adjustments increased to $56.4 million, or 43% of gross revenue, from $40.8 million, or 42%.
- Afrezza gross revenue increased 24%, while net revenue increased 27%. V-Go gross revenue increased 64%, partly because 2023 included a full year of ownership versus seven months in 2022.
- Tyvaso DPI-related revenue from United Therapeutics totaled $124.8 million, including $52.0 million of collaboration and supply revenue and $72.0 million of royalties.
- Research and development expense increased 59% to $31.3 million, primarily due to MNKD-101, INHALE-3 and INHALE-1 activities.
- Stock-based compensation was $17.6 million, compared with $13.4 million in 2022.
Liquidity, Debt and Capital Resources
- Cash and cash equivalents were $238.5 million at December 31, 2023. Short-term investments were $56.6 million and long-term investments were $7.2 million.
- Total principal debt was $272.2 million, with a net carrying amount of $268.7 million. Debt included $230.0 million of senior convertible notes due March 2026, $33.3 million under the MidCap facility due August 2025, and $8.8 million under the Mann Group convertible note due December 2025.
- Contractual cash requirements totaled approximately $595.6 million, including debt, the sale-leaseback financing liability, insulin purchase commitments and capacity fees.
- In December 2023, MannKind received $150.0 million from selling a 1% royalty interest on future Tyvaso DPI net sales. MannKind retains a 9% royalty, but continues to recognize the full 10% royalty as revenue and records the sold portion as non-cash revenue remitted to the purchaser.
- Management stated that available resources and projected operating inflows are expected to fund operations for at least the next twelve months. The filing also acknowledges that operating cash flow has not been consistently positive and that additional financing may be needed for longer-term requirements.
Material Changes Versus the Prior Comparable Period
- Revenue nearly doubled, driven principally by a full year of Tyvaso DPI commercialization, higher Tyvaso DPI demand, increased supply revenue, and growth in Afrezza and V-Go.
- Operating results improved from a $64.1 million operating loss to $8.7 million of operating income; net loss narrowed from $87.4 million to $11.9 million.
- Operating cash flow turned positive, although the 2023 amount included significant customer reimbursements and deferred revenue activity.
- Capital expenditures increased substantially, with $42.4 million spent on property and equipment versus $7.6 million in 2022, reflecting manufacturing capacity expansion.
- Shares outstanding increased to 270.0 million from 263.8 million, and the company increased authorized common shares from 400 million to 800 million.
- The company sold part of its future Tyvaso DPI royalty stream and incurred $0.2 million of related non-cash interest expense in 2023.
Outlook, Commentary, Risks and Unusual Items
- MannKind plans to initiate a Phase 2/3 registrational study of MNKD-101 in the second quarter of 2024 and a Phase 1 study of MNKD-201 in the second quarter of 2024.
- The INHALE-1 pediatric Afrezza study was expected to complete enrollment in the first quarter of 2024. The company continues discussions with the FDA regarding an appropriate long-term Afrezza safety study or registry; no such study had been initiated or budgeted as of the filing.
- A fire at the German contract manufacturer producing MNKD-101 investigational material delayed the planned study start from late 2023 to the second quarter of 2024.
- The company expects to package some Tyvaso DPI stock-keeping units at its Danbury facility in 2024 and is expanding capacity, with expansion costs borne by United Therapeutics.
- Key risks include dependence on United Therapeutics and Tyvaso DPI demand, product adoption and reimbursement, manufacturing and single-source supply risks, regulatory approval and clinical-trial execution, additional capital needs, substantial debt maturities, and potential dilution from convertible debt and equity issuance.
- Afrezza insulin supply is dependent on Amphastar. Remaining purchase commitments were approximately €59.5 million, plus estimated capacity fees of €9.5 million, through at least 2034.
- Accumulated deficit was $3.2 billion and stockholders’ deficit was $246.2 million at year-end. The company remains exposed to operating losses, debt-service requirements and a possible need to raise capital.
- The company reported effective disclosure controls and effective internal control over financial reporting. Deloitte & Touche issued unqualified audit opinions.
Investor Verification Checklist
- Verify the sustainability and quality of 2023 operating cash flow, particularly the effect of customer reimbursements and deferred revenue.
- Track Tyvaso DPI net sales, MannKind’s retained 9% royalty, manufacturing volumes, and the effect of the royalty sale on future cash receipts.
- Assess upcoming debt maturities, MidCap covenant compliance, and the company’s ability to refinance or repay the $230.0 million senior convertible notes due in 2026.
- Monitor Afrezza and V-Go net sales after gross-to-net deductions, including government and commercial rebates, returns and copay assistance.
- Confirm the timing, enrollment and results of the MNKD-101, MNKD-201, INHALE-1 and INHALE-3 programs.
- Review the impact of the Amphastar insulin commitments, capacity fees, foreign-exchange exposure and the existing recognized loss on purchase commitments.
- Evaluate potential dilution from convertible notes, stock-based awards, at-the-market offerings and other authorized shares.